Related references
Note: Only part of the references are listed.Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy
Alastair M. Thompson et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen
Timothy L. Lash et al.
ACTA ONCOLOGICA (2010)
Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment
T. Ramon y Cajal et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis
Bostjan Seruga et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification
Werner Schroth et al.
CLINICAL CANCER RESEARCH (2010)
Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy
Timothy L. Lash et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer
Vincent O. Dezentje et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients
Kazuma Kiyotani et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Methodological and statistical issues in pharmacogenomics
Bas J. M. Peters et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2010)
Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank
Erichsen
Clinical Epidemiology (2010)
Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study
Catherine M. Kelly et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Cyclophosphamide- metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
Priya P. Gor et al.
BREAST CANCER RESEARCH (2010)
CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen
Jean E. Abraham et al.
BREAST CANCER RESEARCH (2010)
Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen
Masatsugu Okishiro et al.
CANCER (2009)
No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications
Thomas P. Ahern et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen
Werner Schroth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Colorectal Hepatic Metastases: Adjuvant Chemotherapy and Survival
David J. Gallagher et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Genotype-guided tamoxifen therapy: time to pause for reflection?
Timothy L. Lash et al.
LANCET ONCOLOGY (2009)
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
J. M. Rae et al.
PHARMACOGENOMICS JOURNAL (2009)
Estrogen receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications
Maj-Lis M. Talman et al.
ACTA ONCOLOGICA (2008)
Danish Breast Cancer Cooperative Group - DBCG: History, organization, and status of scientific achievements at 30-year anniversary
Mogens Blichert-Toft et al.
ACTA ONCOLOGICA (2008)
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise
Susanne Moller et al.
ACTA ONCOLOGICA (2008)
Evaluation of the Potential Excess of Statistically Significant Findings in Published Genetic Association Studies: Application to Alzheimer's Disease
Fotini K. Kavvoura et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment
Y. Xu et al.
ANNALS OF ONCOLOGY (2008)
Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram
T. L. Lash et al.
BRITISH JOURNAL OF CANCER (2008)
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
Kazuma Kiyotani et al.
CANCER SCIENCE (2008)
Impaired tamoxifen metabolism reduces survival in familial breast cancer patients
William G. Newman et al.
CLINICAL CANCER RESEARCH (2008)
Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations
S. P. Myrand et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Estrogen- and progesterone-receptor status in ECOG 2197: Comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory
Sunil S. Badve et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer
Cynthia Owusu et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Comparison of estrogen receptor results from pathology reports with results from central laboratory testing
Laura C. Collins et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Trends in breast-conserving surgery in Denmark, 1982-2002
Thomas P. Ahern et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2008)
Breast cancer recurrence risk in relation to antidepressant use after diagnosis
Jessica Chubak et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism
J. Gjerde et al.
ANNALS OF ONCOLOGY (2008)
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes
Werner Schroth et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study
Soe Soe Thwin et al.
BMC MEDICAL RESEARCH METHODOLOGY (2007)
Using probabilistic corrections to account for abstractor agreement in medical record reviews
Timothy L. Lash et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Recurrences and second primary breast cancers in older women with initial early-stage disease
Ann M. Geiger et al.
CANCER (2007)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Matthew P. Goetz et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer
Pia Wegman et al.
BREAST CANCER RESEARCH (2007)
What clinicians need to know about antioestrogen resistance in breast cancer therapy
Amalia Milano et al.
EUROPEAN JOURNAL OF CANCER (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
SA Nowell et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen
YC Lim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
P Wegman et al.
BREAST CANCER RESEARCH (2005)
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: Prominent roles for CYP3A and CYP2D6
Z Desta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Lack of attenuation in the antitumor effect of tamoxifen by chronic CYP isoform inhibition
D Lehmann et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Re: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
B Ratliff et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Time trends and regional differences in registration, stage distribution, surgical management and survival of breast cancer in Denmark
AR Jensena et al.
EUROPEAN JOURNAL OF CANCER (2003)
Problems of reporting genetic associations with complex outcomes
HM Colhoun et al.
LANCET (2003)
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver
JK Coller et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer
RA Silliman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A comprehensive review of genetic association studies
JN Hirschhorn et al.
GENETICS IN MEDICINE (2002)
Share Paper
